ISCO3 Clinical Trials Follow-up on the preliminary results about the use of O₂/O₃ in the treatment/prevention of Novel Coronavirus Pneumonia (COVID-19).

**Country Region** | **Protocol** | **Remarks / Side effects** |
--- | --- | ---
**BAZIL** | **BAZIL** | Study of the use of ozone therapy adjunctive to the treatment of COVID-19 infections |
**Argentina** | **Argentina** | Multicenter study of the use of ozone therapy in the treatment of severe COVID-19 cases. |
**China** | **China** | MAH 100 mL Blood + 100 mL up to 200 mL, 1-2 times a day. Critical case 2-4 times a day. Time schedule: 10 d. Case report in Innovation (N.Y.), 2020 Nov 25; 1(3): 100060. doi: 10.1016/j.ininn.2020.100060. Patient feels better + Oxygen saturation is improved + 50 % PaO₂ after the first application. A.E.: Allergy. |
**Cuba** | **Cuba** | Rectal insufflation in SARS-CoV2 hosp. patients. Viral Load in 5 days + Clinic. |
**Iran** | **Iran** | Rectal insufflation in SARS-CoV2 hosp. patients. Improve clinicals symptoms and oxidative stress markets. Viral Load in 75% of patients in 6 days. |
**India** | **India** | n=60 Rectal insufflation and minor auto haemotherapy together with standard of care. Outcome in: Int Immunopharmacol. 2020 Dec 23;91:107301. doi: 10.1016/j.intimp.2020.107301. There was improved clinical symptoms status. There was lower viral eradication from host cells. 77% of subjects from the ozonated group were RT-PCR negative on day 5 and 100% subjects were RT-PCR negative on day 10. |
**Italy** | **Italy** | MAH 100-200 mL O₂. 1:1 35→45 µg/mL, daily 4 sessions. Moderate: 40/50 µg/mL. 3 times a day. Severe: MAH 200 mL O₂. 1:1 35→50 µg/mL daily 7 session. O₂ water 60 mL every 6 h. Preliminary results (n=14): Clinical improvement. CT evidence of improvement. Not yet recruiting. |
**Spain** | **Spain** | Ozone Autohemotherapy in COVID19. Tabriz University of Medical Sciences. |
Follow-up: Clinical protocol to study the effect of ozone in SARS-CoV-2 / COVID-19

© ISCO3. 2022